For the July-September period · Net sales for the period were SEK 32.2 million (32.4). · Operating income (EBIT) for the period was SEK 5.1 million (7.3). · Operating margin for the period was 16 percent (22). · Earnings after tax for the period were SEK 3.6 million (6.4). · Earnings per share for the period, basic and diluted, were SEK 0.03 (0.05). · Net sales for the period were SEK 99.8 million (94.5). · Operating income (EBIT) for the period was SEK 15.1 million (13.4). · Operating margin for the period was 15 percent (14). · Earnings after tax for the period were SEK 9.5 million (8.0). · Earnings per share for the period, basic and diluted, were SEK 0.08 (0.06). For the January-September period · Net sales for the period were SEK 99.8 million (94.5). · Operating income (EBIT) for the period was SEK 15.1 million (13.4). · Operating margin for the period was 15 percent (14). · Earnings after tax for the period were SEK 9.5 million (8.0). · Earnings per share for the period, basic and diluted, were SEK 0.08 (0.06). Significant events in the third quarter and after the balance sheet date. · No significant events occurred in the third quarter or after the balance sheet date. President and CEO Anders Karlsson’s comments on the third quarter 2015: “Sales and profitability continued to increase cumulatively for the year and we are seeing an improvement in our operating margin, despite having to compare to a strong third quarter last year. For the first three quarters EBIT rose to 15 percent (14), while the corresponding figure for the third quarter was 16 percent (22). It is gratifying to see such strong performance in the U.S., where sales were up across the board for our key products. The extensive efforts we focused on the American market, initiated in 2014, are now bearing results in the form of increased sales. We now look forward with confidence to the launch of our new product QTYPE®, based on real-time PCR methodology. Our product concept was most recently presented at the end of September at the main HLA typing congress for the American market. Active sales of QTYPE® are expected to commence in early 2016.” For more information please contact: Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se Yvonne Axelsson, CFO Allenex AB, and ph.: +468-508 939 72, e-mail: yvonne.axelsson@allenex.se Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on Nov 27, 2015, at 08.30 CET. Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the Allenex group.
INTERIM REPORT JANUARY – SEPTEMBER 2015 For the
Top 10 Most Recent News Articles
Webull Faces Class Action Suit: Key Deadlines Loom
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon
Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...
Continue Reading
Novo's Semaglutide Shows Promise in MASH Study
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue ReadingTop 5 Most Recently Viewed Articles
Unlocking Interoperability: The Free Partner Edition by interop.io
Unlocking New Potential in Fintech with Free Edition interop.io, known as a frontrunner in desktop interoperability, is set to revolutionize the way fintech companies operate with the introduction of a cost-free edition of their software suite, named io.Connect. This new initiative aims to provide fintechs, regardless of their size or stage, with the opportunity to adopt...
Continue Reading
Massage Envy Celebrates Scholarship Winners and Their Future
Massage Envy Celebrates Scholarship Winners Eight outstanding individuals have been recognized as winners of the Massage Envy National Scholarship Sweepstakes, each receiving a $2,500 scholarship to support their journey into the massage therapy profession. This initiative demonstrates Massage Envy's commitment to fostering the next generation of talented massage...
Continue Reading
Paul Mueller Company Updates Investors on Dividend Plans
Paul Mueller Company Declares Cash Dividend Paul Mueller Company (OTC: MUEL) has some exciting news for its investors. The company has recently announced that its Board of Directors has declared a cash dividend of $0.30 per share on its outstanding common stock. This dividend reflects the company’s ongoing commitment to providing value to its shareholders. Details of...
Continue Reading
Photocure Enhances Leadership with Jane Healy as GM EMEA
Photocure Welcomes Jane Healy as Vice President and General Manager EMEA Photocure ASA (OSE: PHO), known as the Bladder Cancer Company, has made a significant move by appointing Jane Healy as the new Vice President and General Manager for the EMEA region. This strategic decision underscores Photocure's commitment to enhancing its leadership in the uro-oncology sector....
Continue Reading
TDS Hits Bumps but Keeps Shareholders Happy
High Hopes and Hard Hits: TDS in 2026 Listen up, folks. Telephone and Data Systems, Inc. (NYSE: TDS) just popped the hood on their third quarter earnings, and it's a mixed bag with plenty to chew over. Operating revenues are slightly down from last year, but management's got some tricks up their sleeves. CEO Walter Carlson is trumpeting their expanded fiber service...
Continue Reading